Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan cilexetil + amlodipine besylate
- Development stage
- Phase 4
- Lead developer
- HanAll BioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Candesartan cilexetil + amlodipine besylate is a fixed-dose combination (FDC) therapy developed by HK inno.N Corporation (formerly CJ HealthCare) for the management of essential hypertension. The combination leverages two distinct mechanisms of action: candesartan cilexetil, an angiotensin II receptor blocker (ARB), selectively antagonizes the AT1 receptor to inhibit the vasoconstrictive and aldosterone-secreting effects of angiotensin II; amlodipine besylate, a dihydropyridine calcium channel blocker (CCB), inhibits the influx of calcium ions into vascular smooth muscle, leading to direct vasodilation. Together, these agents provide a synergistic reduction in peripheral vascular resistance and blood pressure. This FDC is particularly utilized in patients whose hypertension is not adequately controlled by monotherapy. Additionally, it has been evaluated in Phase 4 clinical trials (such as the REVERT-K study) for concomitant use with lipid-lowering therapies in patients presenting with both hypertension and hyperlipidemia.
- Brand names
- Mahviren
- Other names
- Candesartan/AmlodipineCandesartan cilexetil/amlodipine besylate
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on candesartan cilexetil + amlodipine besylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan cilexetil + amlodipine besylate.